Home » Chelsea Given UK Thumbs Up to Begin Fibromyalgia
Chelsea Given UK Thumbs Up to Begin Fibromyalgia
The UK’s Medicines and Healthcare products Regulatory Agency granted approval to Chelsea Therapeutics to begin a Phase II trial of Droxidopa, alone and combined with carbidopa, for the treatment of fibromyalgia.
Norepinephrine (NE) is a neurotransmitter in the central and peripheral nervous systems that has been linked to both chronic pain and depression. Droxidopa is a synthetic amino acid that the body converts into NE to provide replacement therapy for NE deficiency, according to the company.
The company plans to initiate the multicenter, randomized, double-blind, placebo-controlled, dose-response trial in September.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May